Radiation Oncology Speakers

Sean Collins, MD, PhD, joined his twin brother Brian on the faculty of the cancer center in July of 2006 as an attending physician in radiation oncology. He graduated from the MSTP Program at the University of Michigan in 2001. Professor Collins completed both an internship in surgery and a residency in radiation oncology at Georgetown University Hospital. His area of expertise is prostate cancer, for which he treats patients using the CyberKnife, a technology that allows for more accurate targeting of radiation therapy. Prof Collins is a physician-scientist which means he conducts clinical and laboratory research. The focus of his clinical work is to develop prostate cancer treatment protocols using stereotactic body radiation therapy (SBRT) to minimizing the toxicity of radiation dose escalation. To date, he has treated over 1,300 prostate cancer patients with SBRT and has presented his work at major meeting and published multiple papers on his experience in peer reviewed journals. 

Karyn Goodman, MD, MS is a Professor and Vice Chair for Research in the Department of Radiation Oncology at the Icahn School of Medicine at Mount Sinai. She is also Associate Director for Clinical Research at the Tisch Cancer Institute. Prof Goodman is an internationally recognised expert in gastrointestinal (GI) cancers and has served in numerous leadership roles on committees to establish national treatment guidelines and best practices. She is involved in developing and leading clinical trials evaluating novel multidisciplinary approaches for GI cancers. Prof Goodman serves as the Co-Chair of the NCI GI Steering Committee where she helps to set the strategic priorities for the development of Phase II and III clinical trials in GI cancers conducted through the National Clinical Trials Network (NCTN).    

Prof Goodman received her undergraduate and medical degrees from Stanford University and an MS in Epidemiology from the Harvard School of Public Health. She has published over 200 peer-reviewed scientific articles, review articles and chapters. 

Jeff Michalski, MD, MBA, FASTRO is the Carlos A. Perez Distinguished Professor and Vice Chair of Radiation Oncology at WUSM. Professor Michalski has been a member of the WUSM faculty since 1991, and was named Director of the Clinical Division in Radiation Oncology in 2002 and Professor of Radiation Oncology in 2006. In 2009, he was named Vice Chair and Director of Clinical Programs in Radiation Oncology. Professor Michalski is the current President of the American Society of Radiation Oncology (ASTRO). He is also active in the American Society of Clinical Oncology (ASCO) and co-authored a guideline for bone targeted therapies in prostate cancer. Professor Michalski’s research interests include radiation dose escalation in the management of prostate cancer, conformal therapy to reduce toxicity in late neuro-cognitive effects in children with medulloblastoma, and assessment of quality of life in survivors of adult and childhood malignancies. Professor Michalski has been the Radiation Therapy Oncology Group institutional PI and has served as the Chair of the Radiation Oncology Committee of the NRG Oncology Group. He is a member of the Bladder Cancer Panel of the National Comprehensive Cancer Network. Professor Michalski is also the PI on Phase I-III clinical trials investigating radiation dose escalation in prostate cancer. He is co-Chair of the National Cancer Institute’s GenitoUrinary Steering Committee and oversees clinical research strategies in Prostate, Bladder, and Kidney cancers within the National Clinical Trials Network. Professor Michalski is co-editor for the textbook “Gunderson and Tepper’s Clinical Radiation Oncology, 5^th edition”, which is currently being updated for the 6^th edition.

Matthias Guckenberger, MD, is Chairman of the Department for Radiation Oncology, University Hospital Zurich (USZ), and Professor at the University of Zurich (UZH). Integration of advanced imaging and radiotherapy into multimodality treatment of lung cancer has been a major research focus, especially stereotactic body radiotherapy (SBRT) for early stage NSCLC and oligo-metastatic disease. Safety and efficacy was evaluated in prospective clinical trials, in large multi-institutional and national patterns of care analyses. Mathematical and imaging-based modeling of tumor and normal tissue response to radiotherapy has been another focus. Overall, research has been published in >300 peer-reviewed articles